A Case of Dilated Cardiomyopathy Associated With a Left Atrial Myxoma

Adachi, Hitoshi; Ohshima, Shigeru; Hayashi, Ryohei; Yamamoto, Seigo; Hasegawa, Akira; Yamamoto, Hirohisa; Suzuki, Tadashi; Murata, Katsuyuki; Anzai, Tetsuo

doi:10.2974/kmj1951.36.505

Cited by 1 publication

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two case reports have also described DCM in patients diagnosed with atrial myxoma [133,134]. Adachi et al [133] described a 54-year old female who had echocardiographic and angiographic evidence of markedly reduced LV wall motion and a large LA mass. The histological findings of the biopsied RV specimens were consistent with DCM.…”

Section: Neoplastic Cardiomyopathymentioning

confidence: 99%

“…Case reports suggest diagnosis is often incidental especially when examining for other more common causes of cardiac dysfunction, CM or HF. In all the four case reports on myxoma and HCM or DCM [130][131][132][133], common diagnostic test was transthoracic or transesophageal echocardiography used for the detection of myxoma mass and ventricular hypertrophy and/or dilation. Echocardiogram can detect asymmetric hypertrophy of the basal and mid-anteroseptal wall (consistent with HCM) while CMRI may reveal asymmetric LVH with a thickened interventricular septum and a mass in the LA along the inter-atrial septum [130].…”

Section: Pathophysiologymentioning

confidence: 99%

“…Echocardiography is the best first-lime imaging modality because of its simplicity, wide availability and cost-effectiveness, and detect tumour structure and location as well as hemodynamic alterations induced by the tumour. Cardiac MRI is a complementary technique that is not associated with radiation risk and provides information on tumour vasculature and tissue appearance [133,134]. The management of asymptomatic cardiac myxoma remain a topic of debate because there are no reports clearly favouring conservative or surgical intervention.…”

Section: Pathophysiologymentioning

confidence: 99%

“…The management of asymptomatic cardiac myxoma remain a topic of debate because there are no reports clearly favouring conservative or surgical intervention. However, tumour excision (surgically or by radiotherapy) has been associated with improvement in cardiac function especially in patients with primary cardiac myxoma and familial HCM, which increases the risk of complications [130,133,134]. To improve diagnosis and management, autopsy studies or surgically excised myxoma should be histologically examined for diagnosis as well as the structure should be evaluated by histochemical analysis for cardio-depressant factors particularly in patients with ventricular dysfunction.…”

Section: Pathophysiologymentioning

confidence: 99%

See 3 more Smart Citations

Hematologic/Oncologic cardiomyopathy: A review and pooled analysis of pathophysiology, diagnosis and clinical management

Albakri¹

2019

Clin Med Invest

View full text Add to dashboard Cite

Marked improvement in the accuracy and sensitivity of current diagnostic techniques for cardiac diseases have contributed to the identification of haematologic and oncologic diseases as a possible aetiology of cardiomyopathy (CM). If undiagnosed, the CM may progress to HF and eventually death. This type of CM is exceedingly rare and a precise understanding of its natural cause, pathophysiology, diagnosis and management is undermined by the lack of supporting clinical evidence. Cancer as a direct cause of CM remains controversial. Differentiating cancer-associated CM from chemotherapy-induced CM is difficult since diagnosis of CM is nearly always made after the initiation chemotherapy. Hematologic diseases on the other hand have been classified under restrictive cardiomyopathy (RCM) or dilated cardiomyopathy (DCM) yet they are a distinct clinical entity uniquely characterized by cardiac chamber (atrial and/or ventricular) dilation, diastolic dysfunction and preserved systolic function. Oncologic or haematologic CM has an ominous prognosis although diagnosis is incidental or delayed making management difficult. There is a need to better understand the role of oncologic and/or haematologic diseases in the pathogenesis of CM aimed to improve diagnosis and development of aetiology-specific therapy. Similarly, this review provides an overview of CM in oncology and haematology patients including pathophysiology, presentation, diagnosis and treatment.

show abstract

Section: Neoplastic Cardiomyopathymentioning

confidence: 99%

Section: Pathophysiologymentioning

confidence: 99%

Section: Pathophysiologymentioning

confidence: 99%

Section: Pathophysiologymentioning

confidence: 99%

See 2 more Smart Citations